심혈관계 의약품 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Cardiovascular Drugs Market size is expected to reach USD 195.36 Billion in 2034 from USD 138.21 Billion (2025) growing at a CAGR of 3.92% during 2026-2034.

The global cardiovascular drugs market has grown significantly due to the increasing prevalence of heart-related diseases worldwide. Cardiovascular drugs are used to treat conditions such as hypertension, heart failure, arrhythmias, and coronary artery disease. These medications help regulate blood pressure, improve heart function, and reduce the risk of serious complications.

Several factors are driving the growth of the cardiovascular drugs market. Aging populations, sedentary lifestyles, and unhealthy dietary habits have contributed to a higher incidence of cardiovascular diseases. Advances in pharmaceutical research have led to the development of more effective medications for managing heart conditions.

In the future, the cardiovascular drugs market is expected to continue growing as healthcare systems focus on preventive and long-term treatment strategies. Ongoing research into innovative drug therapies and personalized medicine will improve patient outcomes. With rising awareness of heart health and increasing healthcare investments, demand for cardiovascular drugs will remain strong.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Antihypertensives
• Antihyperlipidemic
• Anticoagulants
• Antiarrhythmics
• Other Drug Classes

By Indication

• Hypertension
• Hyperlipidemia
• Coronary Artery Disease
• Arrhythmia
• Other Indications

By Route of Administration

• Oral
• Parenteral
• Other Routes of Administration

By Distribution Channel

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
• Other Distribution Channels

COMPANIES PROFILED

• Amgen, AstraZeneca, Baxter, Bayer, Boehringer Ingelheim, BristolMyers Squibb, Gilead Sciences, Johnson Johnson, Lupin, Merck, Novartis, Pfizer
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CARDIOVASCULAR DRUGS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Antihypertensives Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Antihyperlipidemic Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Anticoagulants Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Antiarrhythmics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Other Drug Classes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CARDIOVASCULAR DRUGS MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. Hypertension Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Hyperlipidemia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Coronary Artery Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Arrhythmia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Other Indications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CARDIOVASCULAR DRUGS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Other Routes of Administration Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CARDIOVASCULAR DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Other Distribution Channels Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL CARDIOVASCULAR DRUGS MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Drug Class
  • 8.2.2 By Indication
  • 8.2.3 By Route Of Administration
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Drug Class
  • 8.3.2 By Indication
  • 8.3.3 By Route Of Administration
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Drug Class
  • 8.4.2 By Indication
  • 8.4.3 By Route Of Administration
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Drug Class
  • 8.5.2 By Indication
  • 8.5.3 By Route Of Administration
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Drug Class
  • 8.6.2 By Indication
  • 8.6.3 By Route Of Administration
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL CARDIOVASCULAR DRUGS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Amgen
  • 10.2.2 AstraZeneca
  • 10.2.3 Baxter
  • 10.2.4 Bayer
  • 10.2.5 Boehringer Ingelheim
  • 10.2.6 Bristol-Myers Squibb
  • 10.2.7 Gilead Sciences
  • 10.2.8 Johnson & Johnson
  • 10.2.9 Lupin
  • 10.2.10 Merck
  • 10.2.11 Novartis
  • 10.2.12 Pfizer